Home/Pipeline/NP001

NP001

Amyotrophic Lateral Sclerosis (ALS)

Phase 3Active

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 3

Status

Active

Company

Neuvivo

About Neuvivo

Neuvivo is a private, pre-revenue biotech advancing NP001, a novel immunotherapy for ALS. The company has reached alignment with the FDA on an approval pathway, indicating a clear regulatory roadmap for its lead program. Founded in 2015, Neuvivo is built on a neuro-immunologic hypothesis for ALS, aiming to modulate inflammation at the neuromuscular junction to slow disease progression and preserve vital functions like breathing. Its leadership combines scientific, clinical, and biopharmaceutical development expertise.

View full company profile

Therapeutic Areas

Amyotrophic Lateral Sclerosis (ALS)Neurodegenerative Diseases

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active